RXRA and breast carcinoma: We carried out immunoprecipitation assays to assess whether, firstly, there exists a direct or indirect association between RARα, the RXRα heterodimer and Sin3A in breast cancer cell lines and, secondly, whether MAD1-SID treatment would disrupt this interaction.